Similar to KRAS, BRAF mutation has been correlated with lack of response to EGFR inhibitors in patients with advanced CRC and the impact of BRAF mutations on TKI treatment response is currently being investigated [14]. This evidence concerns the gene KRAS and colorectal carcinoma.